Unmasking New Promises: Expanding the Antigen Landscape For Antibody-Drug Conjugates.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Cross-reactivity with normal tissues is one of the key concerns for target selection for antibody-drug conjugates. Probody therapeutics are masked antibodies that can selectively be activated by proteases in the tumor. CX-2029, is a first-in-class Probody targeting CD71 with preliminary efficacy and a tolerable safety profile.See related article by Johnson et al., p. 4521.

Keyphrases

cancer therapy
drug delivery
gene expression
small molecule